Assessment of pain quality in chronic neuropathic and nociceptive pain clinical trials with the neuropathic pain scale

被引:69
|
作者
Jensen, MP
Dworkin, RH
Gammitoni, AR
Olaleye, DO
Oleka, N
Galer, BS
机构
[1] Univ Washington, Sch Med, Dept Rehabil Med, Seattle, WA 98195 USA
[2] Univ Washington, Med Ctr, Ctr Multidisciplinary Pain, Seattle, WA 98195 USA
[3] Univ Rochester, Med Ctr, Dept Anesthesiol, Rochester, NY 14627 USA
[4] Endo Pharmaceut Inc, Chadds Ford, PA USA
来源
JOURNAL OF PAIN | 2005年 / 6卷 / 02期
关键词
pain assessment; neuropathic pain scale; pain quality;
D O I
10.1016/j.jpain.2004.11.002
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Although a number of measures of pain qualities exist, little research has examined the potential for these measures to identify the unique effects of pain treatments on different pain qualities. We examined the utility of the Neuropathic Pain Scale (NPS) for assessing changes in pain qualities after open label lidocaine patch 5% in 3 samples of patients: patients with peripheral neuropathic pain, low back pain, and osteoarthritis. With one exception ("cold" pain in subjects with low back pain), each of the NIPS items showed significant change after open label lidocaine patch. In addition, significantly larger changes were observed for the NIPS items reflecting global pain intensity and pain unpleasantness and for items assessing sharp and deep pain than for items assessing cold, sensitive, and itchy pain. The pattern of changes in pain qualities did not differ across the 3 diagnostic groups, but it did differ from the patterns of changes in pain qualities associated with other analgesic treatments. The results support the potential utility of the NIPS for assessing the patterns of changes in pain qualities that can be observed after pain treatment. Perspective: Pain clinical trials that include measures of pain qualities, such as the NPS, might identify distinct patterns of treatment effects on those pain qualities. This research might be used to help clinicians target analgesics to match the specific qualities associated with a patient's pain and to better understand the mechanisms of analgesic effects in drug development programs. (C) 2005 by the American Pain Society.
引用
收藏
页码:98 / 106
页数:9
相关论文
共 50 条
  • [41] Chronic neuropathic pain in leprosy
    Hietaharju, A
    Croft, R
    Alam, R
    Haanpää, M
    PROCEEDINGS OF THE 9TH WORLD CONGRESS ON PAIN, 2000, 16 : 717 - 723
  • [42] Gabapentin for Chronic Neuropathic Pain
    Moore, Andrew
    Derry, Sheena
    Wiffen, Philip
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2018, 319 (08): : 818 - 819
  • [43] Substantial Nocebo Effect in Clinical Trials for Neuropathic Pain
    Mitsikostas, Dimos Dimitrios
    Papadopoulos, Dimitrios
    NEUROLOGY, 2011, 76 (09) : A649 - A649
  • [44] Opioids and chronic neuropathic pain
    Foley, KM
    NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (13): : 1279 - 1281
  • [45] Duloxetine for neuropathic pain based on recent clinical trials
    Fishbain D.
    Berman K.
    Kajdasz D.K.
    Current Pain and Headache Reports, 2006, 10 (3) : 199 - 204
  • [46] Mechanisms of neuropathic pain and their implications for the design of clinical trials
    Rowbotham, MC
    NEUROLOGY, 2005, 65 : S66 - S73
  • [47] Pharmacotherapy of chronic neuropathic pain
    Otto, J.
    Forstenpointner, J.
    Binder, A.
    Baron, R.
    INTERNIST, 2019, 60 (07): : 711 - 723
  • [48] Antidepressants in Chronic Neuropathic Pain
    Mattia, Consalvo
    Coluzzi, Flaminia
    MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2003, 3 (07) : 773 - 784
  • [49] Pregabalin for neuropathic pain based on recent clinical trials
    Stacey B.R.
    Swift Jr. J.N.
    Current Pain and Headache Reports, 2006, 10 (3) : 179 - 184
  • [50] Methodological issues associated with clinical trials in neuropathic pain
    Gilron, Ian
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2016, 9 (11) : 1399 - 1402